ArticleCold Spring Harbor perspectives in biology2026
Yorkie/YAP Interactors: Fine-Tuning the Hippo Pathway Output.
Article in Cold Spring Harbor perspectives in biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In a canonical view of Hippo signaling, the upstream kinases Hippo/MST and Warts (Wts)/large tumor suppressor (LATS) act as an on/off switch that controls phosphorylation and nuclear access of the key pathway effectors, Yorkie (Yki)/Yes-associated protein 1 (YAP1)/transcriptional coactivator with PDZ-binding motif (TAZ). However, studies in flies and mammals have revealed multiple additional regulators that directly associate with Yki/YAP1, often via PPxY motif/WW domain interactions, and fine-tune Hippo pathway activity. In this review, we highlight such "tuners" located at the endosomal membranes, the cell cortex, and in the nucleus, which regulate Yki/YAP1 turnover, nucleocytoplasmic shuttling, and nuclear activity. These factors can set the overall levels of available Yki/YAP1 via sequestration in various subcellular compartments and endosomal/proteasomal degradation. Nuclear "tuners" can direct the Hippo pathway toward specific cellular outcomes, in part through unique transcriptional programs established in concert with Yki/YAP1. Future efforts will be directed at elucidating how the activities of these multiple regulators are coordinated in vivo.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.